JP2024515770A5 - - Google Patents

Info

Publication number
JP2024515770A5
JP2024515770A5 JP2023565586A JP2023565586A JP2024515770A5 JP 2024515770 A5 JP2024515770 A5 JP 2024515770A5 JP 2023565586 A JP2023565586 A JP 2023565586A JP 2023565586 A JP2023565586 A JP 2023565586A JP 2024515770 A5 JP2024515770 A5 JP 2024515770A5
Authority
JP
Japan
Prior art keywords
benzoxazole
dichlorophenyl
carboxylic acid
crystalline
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023565586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515770A (ja
JP7881608B2 (ja
Filing date
Publication date
Priority claimed from EP21382362.8A external-priority patent/EP4083027A1/en
Application filed filed Critical
Publication of JP2024515770A publication Critical patent/JP2024515770A/ja
Publication of JP2024515770A5 publication Critical patent/JP2024515770A5/ja
Application granted granted Critical
Publication of JP7881608B2 publication Critical patent/JP7881608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023565586A 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法 Active JP7881608B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382362.8 2021-04-26
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (3)

Publication Number Publication Date
JP2024515770A JP2024515770A (ja) 2024-04-10
JP2024515770A5 true JP2024515770A5 (cg-RX-API-DMAC10.html) 2025-03-10
JP7881608B2 JP7881608B2 (ja) 2026-06-29

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565586A Active JP7881608B2 (ja) 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法

Country Status (8)

Country Link
US (1) US20240208915A1 (cg-RX-API-DMAC10.html)
EP (2) EP4083027A1 (cg-RX-API-DMAC10.html)
JP (1) JP7881608B2 (cg-RX-API-DMAC10.html)
CN (1) CN117255781A (cg-RX-API-DMAC10.html)
BR (1) BR112023022116A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023012460A (cg-RX-API-DMAC10.html)
WO (1) WO2022229026A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091534A1 (en) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
WO2026159144A1 (en) 2025-01-22 2026-07-30 Inke, S.A. Solid forms of tafamidis methyl ethyl ketone solvate and processes for their manufacture

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
HUE056583T2 (hu) 2014-09-08 2022-02-28 Pfizer 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof

Similar Documents

Publication Publication Date Title
TWI847144B (zh) 奧美卡替莫卡必爾的合成
JP2023519891A5 (cg-RX-API-DMAC10.html)
JP2005503386A5 (cg-RX-API-DMAC10.html)
JP2015107976A (ja) 結晶形態のテノホビルジソプロキシル及びその製造方法
EP1296951A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2024537795A5 (cg-RX-API-DMAC10.html)
JP2009521414A5 (cg-RX-API-DMAC10.html)
JP2024521412A5 (cg-RX-API-DMAC10.html)
JP2024095561A5 (cg-RX-API-DMAC10.html)
JP2025148397A5 (cg-RX-API-DMAC10.html)
JP2022542803A5 (cg-RX-API-DMAC10.html)
JP2024514090A5 (cg-RX-API-DMAC10.html)
JP6068569B2 (ja) シロドシンの製造方法および中間体
CZ1494A3 (en) Process for preparing diphenyl derivatives, aromatic compound and its use
CN108484567B (zh) 一种1-氟-1,3-丙烷磺酸内酯的制备方法
JP2022540678A5 (cg-RX-API-DMAC10.html)
JP2016510767A5 (cg-RX-API-DMAC10.html)
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
JPS61167673A (ja) (イソキサゾール‐3‐イル)アリールメタノンおよびその製造方法
JP2023530785A5 (cg-RX-API-DMAC10.html)
EP2385046B1 (fr) Phase précurseur et son utilisation pour préparer le sel de magnésium tétrahydraté d'un énantiomère d'oméprazole
JP5485138B2 (ja) エチニルチミジン化合物の精製方法
JP2024529763A5 (cg-RX-API-DMAC10.html)
WO2016202252A1 (zh) 一种合成d-对羟基苯甘氨酸甲酯的方法